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High STAP1 expression in 
DUX4-rearranged cases is not 
suitable as therapeutic target in 
pediatric B-cell precursor acute 
lymphoblastic leukemia
Elisabeth M. P. Steeghs1, Marjolein Bakker1, Alex Q. Hoogkamer1, Judith M. Boer1,2, Quirine 
J. Hartman1, Femke Stalpers1, Gabriele Escherich3, Valerie de Haas4, Hester A. de Groot-
Kruseman4, Rob Pieters2,4 & Monique L. den Boer1,2,4
Approximately 25% of the pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cases 
are genetically unclassified. More thorough elucidation of the pathobiology of these genetically 
unclassified (‘B-other’) cases may identify novel treatment options. We analyzed gene expression 
profiles of 572 pediatric BCP-ALL cases, representing all major ALL subtypes. High expression of STAP1, 
an adaptor protein downstream of the B-cell receptor (BCR), was identified in BCR-ABL1-like and non-
BCR-ABL1-like B-other cases. Limma analysis revealed an association between high expression of 
STAP1 and BCR signaling genes. However, STAP1 expression and pre-BCR signaling were not causally 
related: cytoplasmic Igμ levels were not abnormal in cases with high levels of STAP1 and stimulation of 
pre-BCR signaling did not induce STAP1 expression. To elucidate the role of STAP1 in BCP-ALL survival, 
expression was silenced in two human BCP-ALL cell lines. Knockdown of STAP1 did not reduce the 
proliferation rate or viability of these cells, suggesting that STAP1 is not a likely candidate for precision 
medicines. Moreover, high expression of STAP1 was not predictive for an unfavorable prognosis of BCR-
ABL1-like and non-BCR-ABL1-like B-other cases. Remarkably, DUX4-rearrangements and intragenic 
ERG deletions, were enriched in cases harboring high expression of STAP1.
Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children. Survival rates 
have improved during the last decades and nowadays is approaching 90%. This dramatic increase in survival 
was achieved mostly because of risk-adjusted treatment, therapy intensification, and stem cell transplanta-
tions1. B-cell precursor ALL (BCP-ALL) can be subdivided in different genetic subtypes, which have different 
long-term clinical outcome. However, approximately 25% of the BCP-ALL cases lack sentinel genetic aberra-
tions (KMT2A-rearrangements, BCR-ABL1, ETV6-RUNX1, TCF-PBX1, high hyperdiploidy) and are classified 
as ‘B-other’. We and others showed that part of this B-other group has a gene expression profile similar to that of 
BCR-ABL1-positive ALL cases, and is associated with an unfavorable clinical outcome2,3. Although these patients 
are known to lack the BCR-ABL1 fusion gene, the underlying pathobiology of this subtype remains poorly under-
stood. Cases are enriched for copy number alterations (CNAs) in genes involved in B-cell development, intra-
chromosomal amplification of chromosome 21, dicentric chromosome (9;20), and a subgroup of cases harbors 
kinase activating lesions2–7. Likewise, the remaining non-BCR-ABL1-like B-other cases are a very heterogeneous 
group. Only very recently, chromosomal translocations involving DUX4, ZNF384, and MEF2D were identified in 
these non-BCR-ABL1-like B-other cases8–10. Although kinase activating lesions offer a potentive attractive target 
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for precision medicine, for the remaining group of BCR-ABL1-like and non-BCR-ABL1-like B-other cases, no 
druggable targets have yet been identified.
BCP-ALL cells are immature B-cells in which differentiation is arrested at early immature stages. The pre-
cursor B-cell receptor (pre-BCR), an immature immunoglubulin (Igµ) heavy chain with ‘surrogate’ light-chain 
components, is involved in the expansion and maturation of pre-B cells. For a short period of time, in-frame rear-
ranged VHDJH gene segments are expressed to pass the pre-BCR checkpoint. In absence of this expression, pre-B 
cells are eliminated by programmed cell death11,12. Malignant pre-B cells can evade this pre-B cell checkpoint 
via activation of alternative pathways12. In mature B-cells PI3K-AKT signaling can rescue BCR deficient cells13. 
Signaling of pre-BCR and mature BCR are largely similar14. Targeting BCR signaling is an attractive treatment 
strategy in mature B-cell malignancies and is also being explored in BCP-ALL15–20.
Advanced understanding of the pathobiology of genetically unclassified BCP-ALL cases may identify novel 
treatment options. To identify dysregulated genes in these cases, we analyzed gene expression profiles in leu-
kemia cells of cohort of BCP-ALL patients at initial diagnosis21. High expression levels of the adapter protein 
signal transducing adaptor family member 1 (STAP1) were identified in a subgroup of BCR-ABL1-like and 
non-BCR-ABL1-like B-other patients. STAP1 is a relatively unknown protein, consisting out of Peckstrin homol-
ogy (PH) domains and unique Src homology 2 (SH2) domains, suggesting that STAP1 recruits signaling proteins 
to receptor tyrosine kinases22,23. STAP1 is reported to be a docking protein downstream of Tec protein tyrosine 
kinase (TEC), which is involved in BCR signaling24,25. In addition, reports show enriched expression in hemato-
poietic stem cells and a potential role of STAP1 in microglia activation has been suggested26,27. The current study 
aimed to establish the therapeutic potential of inhibiting STAP1 in the subset of BCP-ALL cases that express high 
levels of STAP1.
Results
Discriminative expression profile of STAP1 in BCR-ABL1-like and B-other cases. To identify 
differentially expressed genes in BCR-ABL1-like and non-BCR-ABL1-like B-other cases, microarrays were per-
formed of a representative pediatric BCP-ALL cohort of 572 cases at initial diagnosis21. Limma analyses revealed 
STAP1 to be the probeset with the highest fold-change in BCR-ABL1-like and non-BCR-ABL1-like B-other 
patients compared to remaining BCP-ALL cases (fold change = 2.88, adjusted p-value < 0.0001; Supplementary 
Table S1). Strikingly, this elevated expression was characteristic for a subset of patients reflecting about 20% of 
BCR-ABL1-like and non-BCR-ABL1-like B-other cases (Fig. 1a, henceforth: STAP1-high cases). The remaining 
BCR-ABL1-like and non-BCR-ABL1-like B-other cases (henceforth: STAP1-low) had STAP1 expression levels 
comparable to those observed in other ALL subtypes and mononuclear bone marrow cells of healthy controls 
(Supplementary Fig. S1). Microarray results were validated using RT-qPCR (Fig. 1b, Supplementary Fig. S1). 
Subsequently, we analyzed which genes were associated with high expression levels of STAP1. Limma analy-
ses revealed 8894 probesets to be differentially expressed between STAP1-high and STAP1-low cases (adjusted 
p-value < 0.05; Supplementary Table S2). Ingenuity pathway analysis was performed to identify pathways asso-
ciated with these differentially expressed genes. EIF2 signaling, mTOR signaling, regulation of eIF4 and p70S6K 
signaling, B cell receptor signaling (BCR), and AMPK signaling included the top five differentially regulated 
canonical pathways (Supplementary Fig. S1). Identification of the BCR signaling pathway was a striking obser-
vation, as STAP1 is reported to be a docking protein downstream of TEC in this pathway24,25. Since the signaling 
pathways activated by pre-BCR and mature BCR are highly overlapping14, we hypothesized a similar function for 
STAP1 in the downstream signaling cascade of the pre-BCR. Taken together, the association between STAP1 and 
Figure 1. Discriminative expression of STAP1 in BCR-ABL1-like and B-other cases. (a) 2log expression 
levels of Affymetrix probeset 220059_at in 572 BCP-ALL cases. The dotted line represents the 80th percentile 
of BCR-ABL1-like and B-other cases. Grey lines represent the median expression values of subtype groups. 
(b) Microarray expression levels were validated using RT-qPCR, as shown by a high spearman correlation 
coefficient. (c) Expression values of STAP1 in 6 STAP1-high and 17 STAP1-low cases detected by RT-qPCR. 
Independent samples T-test. The grey lines represent the median of the STAP1-high and the STAP1–low group. 
Mann-Whitney U test. **p < 0.01.
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the BCR signaling cascade may suggest an activated pre-BCR signaling pathway in a subset of BCR-ABL1-like and 
non-BCR-ABL1-like B-other cases. This hypothesis was further explored since it may offer a targeted treatment 
strategy for these cases17–20.
High levels of STAP1 and pre-BCR signaling are not causally connected. We studied whether 
high levels of STAP1 associated with high expression of the pre-BCR complex. To determine in-frame rearrange-
ments of immunoglobulin heavy chain VHDJH gene segments (indicative for a functional pre-BCR), cytoplasmic 
Igµ (CyIgµ) levels were measured in 142 BCR-ABL1-like and non-BCR-ABL1-like B-other cases. 14 of the 32 
(44%) STAP1-high cases showed positivity (>30% CyIgµ+ cells) compared with 31 of the 110 (28%) STAP1-low 
cases (Fisher exact test. p = 0.13). This result suggests that STAP1-high and STAP1-low cases do not differ in the 
number of pre-BCR positive cells. In addition, we examined whether STAP1 expression itself may be induced by 
pre-BCR signaling. Therefore, the BCP-ALL cell lines Nalm6 and Kasumi-2 (high and low STAP1 expression, 
respectively) were stimulated for 4 days with 1 µg anti-IgM antibody. To confirm activation of pre-BCR signaling 
by the anti-IgM antibody, phosphorylation levels of AKTSer473 were analyzed (Supplementary Fig. S2). Stimulation 
of the pre-BCR did not increase STAP1 expression levels in the STAP1-high cell line Nalm6. In the STAP1-low 
cell line Kasumi-2 only a slight increase was detected in time (~1.3–1.6 fold; Fig. 2). Taken together, these results 
suggest that high levels of STAP1 and pre-BCR signaling are not causally connected.
Silencing of STAP1 does not affect cell viability and drug sensitivity. To elucidate the role of STAP1 
in BCP-ALL survival, STAP1 expression was silenced by four different shRNAs in the BCP-ALL cell lines Nalm6 
and Kasumi-2. The knockdown efficiency at mRNA level ranged from 50–80% for both cell lines and was con-
firmed on protein level (Fig. 3a, Supplementary Fig. S3,4). Three out of four shRNA constructs did not alter the 
proliferation rate and viability of Nalm6 cells, despite effective knockdown. Only shRNA-2 reduced those param-
eters in Nalm6 cells, but not in Kasumi-2 cells (Fig. 3b). Seven days after transduction, the majority of leukemic 
cells remained alive in both cell lines and in all knockdown conditions (Fig. 3c). These data suggest that STAP1 is 
not essential for the survival of BCP-ALL cells.
Next, we studied whether silencing of STAP1 affected sensitivity for inhibitors of pre-BCR (ibrutinib) and 
mTOR signaling (rapamycin), and the ALL spearhead drug prednisolone. Silencing of STAP1 did not alter the 
sensitivity to these compounds in the Nalm6 or Kasumi-2 cell lines (Fig. 4). To elucidate in which other signaling 
pathway STAP1 may be involved, the phosphorylation status of 17 proteins covering multi-signaling pathways 
was examined (Fig. 5). Silencing STAP1 did not alter the phosphorylated levels/ activation of Src-family, PI3K, 
Ras, Stat, JNK, p38 and NFκB kinase signaling members, nor of the reported STAP1 target in Ramos cells, i.e. 
phosphorylated level of CREBSer13325. Taken together, STAP1 inhibition did not affect the survival and prolif-
eration of the BCP-ALL cell lines Nalm6 and Kasumi-2 or the phosphorylated levels of downstream signaling 
molecules, nor did knockdown result into sensitization for prednisolone or signaling inhibitors (ibrutinib and 
rapamycin).
Aberrations in B-cell development genes and clinical characteristics. Genes involved in B-cell 
development are frequently altered in BCR-ABL1-like patients2,3. Therefore, frequencies of lesions in genes 
involved in lymphoid differentiation, proliferation, cell cycle and transcription were studied in STAP1-high and 
STAP1-low BCR-ABL1-like and non-BCR-ABL1-like B-other cases. Copy number alterations affecting EBF1, 
PAR1, and ETV6 were virtually absent in STAP1-high cases compared to a frequency ranging from 10.9–22.4% in 
STAP1-low cases (Fisher exact test, p < 0.05; Table 1). More strikingly, high expression of STAP1 was associated 
with intragenic deletion of the ETS transcription factor ERG: 27.6% (8/29) in STAP1-high cases compared to 
0.8% (1/133) in STAP1-low cases (p < 0.0001, odds ratio = 47.7; Table 1). Deletions of ERG are associated with 
a favorable prognosis in genetically unclassified high-risk pediatric BCP-ALL28–30. The five-year CIR and EFS of 
STAP1-high and STAP1-low BCR-ABL1-like and non-BCR-ABL1-like B-other cases did not significantly differ 
in our cohort, although STAP1-high cases showed a trend for a more favorable outcome (Fig. 6a,b). STAP1-high 
cases had a higher median age (Mann-Whitney U test; p = 0.013; 9 years, range 2–16) than STAP1-low cases (6 
Figure 2. Pre-BCR signaling and STAP1 expression. The BCP-ALL cell lines Nalm6 and Kasumi-2 were 
stimulated with 1 µg anti-IgM for 1, 24, 48, 72 or 96 hours. Expression levels of STAP1 were examined using 
RT-qPCR. Linear values normalized to RPS20 expression are shown. Mean ± SEM of three independent 
experiment. Independent samples T-test. * p < 0.05.
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years, range 1–18). Remaining clinical characteristics, i.e. white blood cell count, in vivo prednisolone response at 
day 8, gender, and MRD levels did not differ (Supplementary Table S3). In addition, ex vivo cytotoxicity of pred-
nisolone, vincristine, daunorubicin, l-asparaginase, 6-thioguanine, 6-mercaptopurine was measured in primary 
leukemic cells. No difference in cytotoxicity of these compounds was observed in STAP1-high and STAP1-low 
BCR-ABL1-like and non-BCR-ABL1-like B-other cells (Fig. 6c–h).
Interestingly, ERG deletions were very recently shown to be a hallmark of a newly identified BCP-ALL subtype, 
involving rearrangements of the double homeobox transcription factor DUX48–10,31. The association between high 
STAP1 levels and ERG deletions prompted us to investigate the presence of DUX4 rearrangements in our cases. 
To this aim, we screened an independent BCP-ALL cohort (n = 2 KMT2A-rearranged, n = 1 BCR-ABL1, n = 21 
B-other, n = 17 ETV6-RUNX1, n = 21 high hyperdiploid) for DUX4-rearrangements and ERG deletions. Four 
DUX4-rearranged cases were detected in the B-other group, of which two showed high expression levels of STAP1 
(Fig. 7). None of these DUX4-rearranged cases or remaining B-other cases harbored an ERG deletion. In addition, 
we analyzed the association between STAP1, ERG, and DUX4 using a publically available dataset of 304 BCP-ALL 
cases10,32. Similar to the observation made in our own patients, DUX4-rearranged cases displayed higher levels of 
STAP1 mRNA (Supplementary Fig. S6), which was independent of intragenic ERG deletions.
Figure 3. STAP1 knockdown does not affect leukemic cells survival. Nalm6 and Kasumi-2 cells were 
transduced via spin-infection with shRNAs targeting STAP1 or scrambled control vectors. Values represent 
mean ± SEM of four independent experiments. Independent sample T-test. **p < 0.01; *p < 0.05. (a) 
Knockdown efficacy was determined three and seven days after transduction using RT-qPCR. STAP1 expression 
relative to RPS20 was calculated. Relative expression values towards the two scrambled controls are depicted. 
(b) Proliferation of Nalm6 and Kasumi-2 cells was measured for four days. At day 0 (3 days after transduction) 
cells were plated at equivalent concentrations. The next four days cell concentrations were detected using the 
MACSQuant and PI staining. Cell numbers (x106) are shown on the y-axis. (c) Seven days after transduction, 
viability of the cells was determined using AnnexinV and PI staining. Viability relative to scrambled control 
samples is shown.
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Taken together, high expression of STAP1 is not associated with (long-term) clinical outcome parameters or 
ex vivo drug resistance. However, the STAP1-high group is enriched for DUX4-rearrangements and intragenic 
ERG deletions.
Discussion
The aim of the current study was to assess the potential of STAP1 as a therapeutic target in BCP-ALL cases. 
High expression of STAP1 was detected in a subset of BCR-ABL1-like and non-BCR-ABL1-like B-other patients. 
Interference with STAP1 did not induce cell death or block proliferation nor did it make cells more sensitive 
to BTK (ibrutinib) and mTOR (rapamycin) inhibitors. In addition, high expression levels of STAP1 were not 
associated with a poor five-year EFS, high MRD levels, or ex vivo resistance to chemotherapeutic drugs that are 
traditionally used in the treatment of BCP-ALL. Taken together, these results suggest that STAP1 is not a likely 
target for precision medicines in childhood ALL.
STAP1 is a relatively unknown gene. A potential role for the protein in neuronal apoptosis and degeneration 
has been suggested26. However, involvement of the protein in cancer thus far remains elusive. We studied the gene 
expression profiles of STAP1-high BCP-ALL cases. The observed association between high expression of STAP1 
Figure 4. STAP1 knockdown does not sensitize cells towards prednisolone, ibrutinib or rapamycin.  
(a–c) The efficacy of prednisolone (a), ibrutinib (b), and rapamycin (c) was tested in Nalm6 and Kasumi-2 
cells, in which STAP1 was silenced. Three days after transduction, Nalm6 and Kasumi-2 cells were exposed to a 
concentration range of the indicated compounds. After four days, viability was quantified using an MTS assay. 
Values represent mean ± SEM of four independent experiments of Nalm6 and three independent experiments 
of Kasumi-2.
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Figure 5. STAP1 knockdown does not affect common signaling pathways. Expression of 17 proteins 
was determined using a fluorescent bead-based immunoassay in Nalm6 cells after knockdown of STAP1. 
Fluorescent intensity values relative to GAPDH are depicted. Expression was measured three and seven days 
after transduction. Infection and selection for stably transduced cells required three days. Subsequently, 
proliferation, viability and MTS assays were initiated, which took four days. mRNA and protein expression 
levels were examined after selection (day 3) and at the end of these functional experiments (day 7). At day 7, 
not enough material was available of Nalm6 cells, which were transduced with shRNA-2. Values represent 
mean ± SEM of four independent experiments at three days after transduction and three independent 
experiments at seven days after transduction.
www.nature.com/scientificreports/
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and BCR signaling is in concordance with the few reports suggesting that STAP1 is a docking protein downstream 
of the BCR24,25. Targeting the BCR pathway is an effective treatment strategy for mature B-cell malignancies and 
this approach is also being explored in BCP-ALL15–20. The overlap in downstream molecules involved in pre-BCR 
and BCR signaling14, prompted us to investigate the connection between STAP1 expression and the pre-BCR 
pathway. However, CyIgµ expression (indicative for a functional pre-BCR) was not enriched in STAP1-high cases, 
and stimulation of leukemic cell lines with IgM only marginally induced expression STAP1 in one cell line. In 
addition, silencing of STAP1 did not reduce the proliferation rate and viability of leukemic cells in the majority 
of shRNAs tested. Strikingly, knockdown of STAP1 did also not affect phosphorylation levels of marker proteins 
involved in pre-BCR signaling (SRC) or other signaling pathway (PI3K, Ras, Stat, JNK, p38, NFκB), which are 
important for proliferation and survival of cells. In addition, silencing of STAP1 did not affect the phosphorylated 
levels of CREB, which is a downstream target of STAP1 in the Ramos/Burkitt lymphoma cell line25. The question 
remains regarding the signaling pathway in which STAP1 is involved. Nevertheless, our results imply that STAP1 
is not an oncogenic driver and that the high expression is most likely a consequence of another transforming 
event.
Interestingly, we observed intragenic deletions of the transcription factor ERG in a part of the STAP1-high 
cases. The proto-oncogene ERG is a regulator of hematopoiesis, including B-cell development33,34, and is impli-
cated in the pathogenesis of Ewing sarcoma, prostate cancer, and acute myeloid leukemia35–37. Recently, ERG 
deletions were shown to be a hallmark of a novel identified subtype of BCP-ALL, i.e. DUX4-rearranged ALL8–10. 
DUX4 encodes a double homeobox transcription factor and is located within the D4Z4 macrosatellite repeat 
array on 4q35 and 10q26. This pro-apoptotic gene is normally expressed in germline and testis cells, but epigenet-
ically silenced in somatic cells38,39. DUX4-fusion proteins, but not wildtype DUX4, were shown to have oncogenic 
potential in NIH3T3 fibroblasts9. The pathway induced by DUX4-rearrangements is yet unknown. In the present 
work we show that high expression of STAP1 is characteristic for DUX4-rearranged cases (Fig. 7, Supplementary 
Fig. S6). The association between STAP1 and DUX4 was independent of ERG deletions. Therefore, upregulation 
of STAP1 may be a consequence of the oncogenic signaling pathway induced in DUX4-rearranged cases which is 
independent of concomitant ERG deletions. Further unraveling of the signaling pathway downstream of DUX4 
will be crucial for the development of targeted treatment strategies for this genetic BCP-ALL subtype.
Methods
A detailed description of all methods can be found in the supplement.
Processing of primary patient material. Bone marrow and/or peripheral blood samples were obtained 
from children (1–18 years) with newly diagnosed ALL. Written informed consent was obtained from parents 
or guardians to use excess of diagnostic material for research purposes, as approved by the Medical Ethics 
Committee of the Erasmus Medical Center, The Netherlands. Studies were conducted in accordance with the 
Declaration of Helsinki. Mononuclear cells were isolated using Lymphoprep gradient separation and the leu-
kemic blast percentage was determined microscopically by May-Grünwald Giemsa stained cytospin prepara-
tions, as described previously40. Samples were enriched to >90% leukemic cells by depleting normal cells, using 
anti-CD marker coated magnetic beads, i.e. anti-CD3, anti-CD14, anti-CD15, anti-CD33, and/or H1 beads 
(IQ Products, Groningen, The Netherlands) combined with pan mouse IgG dynabeads (Invitrogen, Bleiswijk, 
Netherlands). Primary leukemic cells were maintained in RPMI-1640 Dutch modification (Life Technologies, 
Breda, Netherlands) supplemented with 20% fetal calf serum (Integro, Zaandam, Netherlands), with 0.1% 
insulin-transferrin-sodium selenite (Sigma-Aldrich, Zwijndrecht, Netherlands), 0.4 mM glutamine (Invitrogen), 
0.25 μg/ml gentamycine (Thermo Scientific, Breda, Netherlands), 100 IU/ml penicillin (Thermo Scientific), 
100 μg/ml streptomycin (Thermo Scientific), 0.125 μg/ml fungizone (Thermo Scientific).
Patients were treated according to the Dutch Childhood Oncology Group ALL8, ALL9, ALL10 protocol, or 
the COALL-06-97 and COALL-07-03 study protocols41–45. The major subtypes (high hyperdiploid (51–65 chro-
mosomes), ETV6-RUNX1, TCF3-PBX1, KMT2A-rearranged, BCR-ABL1) were determined using fluorescent in 
situ hybridization and (RT-)PCR by reference laboratories. Cases negative for these lesions were classified as 
B-other. Among these B-other cases, BCR-ABL1-like cases were identified using the 110-probeset gene expression 





IntervalNumber Percentage Number Percentage
IKZF1 deletion 8/36 22.2 58/156 37.2 0.120
EBF1 deletion 0/36 0.0 17/156 10.9 0.046 0.00 0.00 1.00
PAX5 aberration 10/36 27.8 69/156 44.2 0.091 0.49 0.20 1.13
CDKN2A/B deletion 15/36 41.7 77/156 49.4 0.460
RB1 deletion 1/36 2.8 14/156 9.0 0.310
BTG1 deletion 1/36 2.8 10/156 6.4 0.690
ETV6 deletion 1/36 2.8 35/156 22.4 0.004 0.10 0.00 0.64
PAR1 deletion 0/36 0.0 19/156 12.2 0.027 0.00 0.00 0.87
ERG deletion 8/29 27.6 1/131 0.8 3.80E-06 47.68 5.91 2183.65
Table 1. Copy Number Alterations in B-cell development genes. Fisher’s Exact test p-values are shown. Values 
shown in bold if p < 0.05; Odds ratios are only given if p-values in Fisher’s Exact test were below 0.1.
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classifier2. In addition, immunophenotyping was performed, including cytoplasmic Igμ (CyIgμ) expression. 
Samples containing more than 30% leukemic cells expressing CyIgμ were labelled as CyIgμ-positive.
Figure 6. Ex vivo drug response and outcome is not affected by STAP1 overexpression. (a,b) The association 
between high expression levels of STAP1, and cumulative incidence of relapse (CIR) and event-free-survival 
(EFS) was examined. Patients were stratified according to treatment protocol (i.e. COALL-97 or -03, or the 
DCOG protocols ALL8, ALL9, or ALL10). CIR was estimated using a competing risk model with relapse and 
non-response as event and death as competing event. The Gray’s test was applied. Relapse, non-response, 
secondary malignancies and death were considered as events for EFS. EFS rates were determined using Cox 
regression, and compared using the Wald test. (c–h) Leukemic cells were exposed for four days to an increasing 
concentration range of prednisolone (µg/ml), vincristine (µg/ml), L-asparaginase (IU/ml), daunorubicin (µg/
ml), 6-mercaptopurine (µg/ml), and 6-thioguanine (µg/ml). Cell survival was measured using an MTT assay. 
To compare LC50-values, the Mann-Whitney U test was applied. BO = non-BCR-ABL1-like B-other BCP-ALL 
cases. BAL = BCR-ABL1-like BCP-ALL cases.’
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Cell lines. The human BCP-ALL cell lines Nalm6 and Kasumi-2 were obtained from the German Collection 
of Microorganisms and Cell lines (DSMZ, Braunschweig, Germany). Cells were cultured in RPMI-1640 medium, 
supplemented with 10% fetal calf serum (Bodinco BV, Alkmaar, Netherlands), 100 units/ml penicillin, 100 μg/
ml streptomycin and 0.125 μg/mL fungizone (Life Technologies). The identity of cell line was routinely verified 
by DNA fingerprinting. The B-other cell line Nalm6 expressed high levels of STAP1 and TCF3-PBX1-positive 
Kasumi-2 cells had low expression levels of STAP1. For stimulation experiments, cells were exposed to 1 µg 
anti-IgM F(ab′)2 (SouthernBiotech, Birmingham, AL, USA).
STAP1 expression status. Microarrays (Affymetrix U133 Plus 2 Santa Clara, California, USA) were 
analyzed of a previously published cohort of 572 BCP-ALL patients at initial diagnosis (GSE13351)21, 
in which all major ALL subtypes were represented (BCR-ABL1-positive n = 24, BCR-ABL1-like B-other 
n = 92, non-BCR-ABL1-like B-other n = 113, ETV6-RUNX1-positive n = 172, high hyperdiploid n = 141, 
KMT2A-rearranged n = 11, TCF3-RUNX1-positive n = 19). Gene expression profiles of BCR-ABL1-like and 
non-BCR-ABL1-like B-other samples were compared to remaining BCP-ALL cases, using Limma R Package 
(version 3.26.9) in R 3.0.1. BCR-ABL1-like and non-BCR-ABL1-like B-other cases with signal intensity val-
ues of both STAP1 probesets (220059_at and 1554343_a_at) above the 80th percentile of BCR-ABL1-like and 
non-BCR-ABL1-like B-other cases were classified as STAP1-high (see also Fig. 1a). Remaining BCR-ABL1-like 
and non-BCR-ABL1-like B-other cases were classified as STAP1-low.
Figure 7. STAP1 expression and DUX4-rearrangements. RNAseq analyses were used to determine DUX4 
and STAP1 expression levels in an independent BCP-ALL cohort (n = 2 KMT2A-rearranged, n = 1 BCR-
ABL1, n = 21 B-other, n = 17 ETV6-RUNX1, n = 21 high hyperdiploid). Fastq-files with paired-end data were 
aligned to one DUX4 gene and the STAP1 GRCh37 reference sequence using STAR 2.5.0b. Read counts were 
determined with HTSeq-count version 0.6.1p1. Grey lines represent the median expression values. (a) DUX4 
expression values are depicted as Fragments Per Kilobase per Million mapped (FPKM). DUX4-partner genes 
were identified using NCBI blast, in which unknown sequences after the breakpoint were aligned52. DUX4-
allignement of 4 DUX4-rearranged cases and 4 non-DUX4-rearranged B-other cases is shown. (b) STAP1 
expression values are depicted as FPKM.
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Quantitative reverse transcription PCR (RT-qPCR). mRNA expression levels of STAP1 and RPS20 
were quantified using real-time PCR analysis on an ABI Prism 7700 sequence detection system (PE Applied 
Biosystems). RNA was extracted using the RNeasy mini kit (Qiagen, Hilden, Germany), after which cDNA 
was synthesized. STAP1 and RPS20 mRNA levels were quantified by incorporation of SYBR Green (Thermo 
Scientific) by quantitative real-time PCR, using STAP1-specific primers (5′-ccaggaaaggttaaagattact-3′ and 
5′-ttccccactttctgtgtt-3′) and RPS20-specific primers (5′-aagggctgaggatttttg-3′ and 5′-cgttgcggcttgttag-3′). Relative 
STAP1 mRNA levels as percentage of RPS20 levels were calculated using the comparative cycle time (Ct) method; 
2−ΔCt × 100%, whereby ΔCt = CtSTAP1 − CTRPS20.
Transfection, virus production and transduction. To knockdown STAP1 expression, four pLKO.1-puro 
Mission® vectors (Sigma-Aldrich) containing a short hairpin RNA (shRNA) targeting STAP1 (TRCN0000065083, 
TRCN0000065084, TRCN0000065085, TRCN0000065087; shRNA-1, shRNA-2, shRNA-3, shRNA-4, respec-
tively) were used. The Mission® pLKO.1-puro Non-Mammalian shRNA Control Plasmid DNA (SHC002) and 
Mission® pLKO.1-puro Luciferase shRNA Control Plasmid DNA (SHC007) were used as scrambled control vec-
tors (NSC-1 and NSC-2, respectively).
Vectors were transfected in HEK293T cells, using XtremeGene, 3.7 μg psPAX2 (Addgene plasmid 
12260; Addgene, Cambridge, MA, USA), 1.6 μg pMD2.G (Addgene plasmid 12259) and 10.7 μg of one of the 
pLKO.1-puro Mission® vectors. The second and third day after transfection virus was harvested and concen-
trated using ultracentrifugation for 2 hours at 32.000 rpm and 4 °C. Concentrated virus was aliquoted and stored 
at −80 °C. Leukemic cells were spin-infected and puromycin selection was initiated 24 hours after transduction. 
Transduction efficiency was determined using a titration range. After 48 hours of puromycin selection (1 µg/ml) 
cell viability was measured using flow cytometry (MACSQuant) and propidium iodide (PI; Invitrogen). Viability 
of transduced cells as percentage of viability of non-transduced cells was defined as the transduction efficacy. 
Proliferation was measured for 5 days using flow cytometry (MACSQuant) and PI staining. At day 5, viability was 
quantified using Annexin V (Biolegend, London, UK) and PI staining.
Ex vivo drug resistance. Ex vivo cytotoxicity of prednisolone, vincristine, L-asparaginase, daunorubicin, 
6-mercaptopurine and 6-thiguanine in primary samples was evaluated using 3-(4,5-dimethylthiazolyl-2)-2,5-dip
henyltetrazolium bromide (MTT), as previously described40. After four days of culture, viability was quantified by 
measuring the optical density values after 6 hours of incubation with MTT. LC50 values were compared using the 
Mann-Whitney U test. In vitro cytotoxicity of prednisolone, ibrutinib and rapamycin in cell lines was evaluated 
using 3-(4,5-dimethylthiazolyl-2)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; MTS) and 
phenazine methosulfate (PMS). Cells were exposed to a dilution series of agents (prednisolone: 0.06 to 250 μg/
mL; ibrutinib: 0.16 to 40 μM; rapamycin: 4 nM to 40 μM) in a 96 wells plate for four days at 37 °C and 5% CO2, 
after which viability was quantified.
Multiplexed fluorescent bead-based immunoassay (Luminex). Cells were lysed in RIPA buffer 
(ThermoFisher Scientific) with freshly added protease and phosphatase inhibitors. Protein concentration was 
determined using the BCA method (Thermo Scientific). Expression of 17 proteins was determined in 10 µg lysate, 
using a fluorescent bead-based immunoassay (multi-pathway magnetic bead 9-plex and the 8-plex human Src 
family kinase kit; Merck Millipore, Amsterdam, Netherlands) according to the manufacturer’s protocol. GAPDH 
beads (Merck Millipore) were used as internal reference for each sample.
Multiplex Ligation-Dependent Probe Amplification (MLPA). To identify genomic lesions in 
IKZF1, CDKN2A, CDKN2B, ETV6, PAX5, RB1, BTG1, EBF1, and PAR1 (CSF2RA/IL3RA/CRLF2), the SALSA 
P335 ALL-IKZF1 (a3) and the SALSA P202 Multiplex Ligation-dependent Probe Amplification (MLPA) assays 
(MRC-Holland, Amsterdam, Netherlands) were used as described previously4,21,46. A peak ratio < 0.75 was used 
to determine deletions, 0.75 ≤ peak ratio ≤ 1.3 for normal copy number, and peak ratio > 1.3 for gain. Loss of 
either CDKN2A or CDKN2B was coded as CDKN2A/B deletion and intragenic amplifications of PAX5 were 
coded as aberration.
Genome-wide DNA copy number arrays (array-CGH). To identify ERG deletions, genome-wide 
DNA copy number arrays were performed as described previously4. Briefly, Agilent SurePrint G3 Hmn 4 × 180 K 
arrays (Agilent Technologies, Amstelveen, the Netherlands) were co-hybridized with 1 μg patient DNA labeled 
with ULS-Cy5 and 1 μg reference genomic DNA male pool (G147A, Promega, Leiden, the Netherlands) labeled 
with ULS-Cy3 (Agilent Genomic DNA ULS Labeling Kit). Using median log ratios, data were normalized using 
the CGHcall47 version 2.14.0, centralized using CGHnormaliter48 version 1.8.0, and segmented and called using 
CGHcall default settings (−1 for loss, 0 for diploid, 1 for gain and 2 for amplification) in R version 2.14.1.
Clinical characteristics and statistics. To identify whether copy number alterations (CNAs), clinical 
characteristics or CyIgμ expression were depleted or enriched in cases harboring high expression levels of STAP1, 
the Fisher’s exact test in R (version 3.2.1) was applied. Cumulative incidence of relapse (CIR) was estimated 
using a competing risk model and significance was determined using the Gray’s test. Relapse and non-response 
(counted at day 79 of therapy) were considered as events and death as competing event. Event-free survival (EFS) 
probabilities were estimated using cox regression and compared using the Wald test. Relapse, non-response, sec-
ondary malignancies and death were counted as events. Outcome analyses were performed in R (version 3.2.1), 
using the packages cmprsk version 2.2-749, mstate version 0.2.750, and survival version 2.37-451. Five-year EFS and 
CIR are reported.
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SNP arrays. Genome-wide human SNP arrays 6.0 (Affymetrix) were performed according to the manufac-
turer’s protocol. Raw probe values were extracted from CEL files and processed with the R package aroma.affy-
metrix version 3.1.0. Samples were compared to reference values, which was the average of 53 diploid BCP-ALL 
and T-ALL samples. To correct for bias introduced by differences in GC content of DNA fragments, the R package 
ArrayTV version 1.12.0 was used. To compare the logR values of the copy numbers between samples a centrali-
zation step was performed, using the R package CGHnormaliter version 1.28.0. Data were called using CGHcall 
version 2.36.0 default settings (−2 for double loss, −1 for loss, 0 for diploid, 1 for gain and 2 for amplification) in 
R version 3.3.3.
RNAseq. mRNA was extracted from total RNA and amplified using random hexamer primers. Further 
Library construction was done using a strand-specific protocol. Sequencing was performed on a HiSeq. 2000 
producing 151 bp paired-end reads with a median library size of 50 million read pairs per sample. Fastq-files 
with paired-end data were aligned to the GRCh37 reference sequence using STAR 2.5.0b. Read counts were 
determined with HTSeq-count version 0.6.1p1. To determine DUX4 expression, the fastq-files were aligned to 
the DNA sequence of the gene ENSG00000259128.1 plus 200 bp down- and upstream. DUX4-partner genes were 
identified using NCBI blast, in which unknown sequences after the breakpoint were aligned52.
Data availability. The datasets generated during and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
References
 1. Pui, C. H. & Evans, W. E. A 50-year journey to cure childhood acute lymphoblastic leukemia. Seminars in hematology 50, 185–196, 
https://doi.org/10.1053/j.seminhematol.2013.06.007 (2013).
 2. Den Boer, M. L. et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide 
classification study. Lancet Oncol 10, 125–134, https://doi.org/10.1016/S1470-2045(08)70339-5 (2009).
 3. Mullighan, C. G. et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. The New England journal of medicine 360, 
470–480, https://doi.org/10.1056/NEJMoa0808253 (2009).
 4. Boer, J. M. et al. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia. Oncotarget 8, 4618–4628, 
https://doi.org/10.18632/oncotarget.13492 (2017).
 5. Imamura, T. et al. Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase 
fusions in Japan. Blood cancer journal 6, e419, https://doi.org/10.1038/bcj.2016.28 (2016).
 6. Roberts, K. G. et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. The New England journal of 
medicine 371, 1005–1015, https://doi.org/10.1056/NEJMoa1403088 (2014).
 7. Roberts, K. G. et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. 
Cancer cell 22, 153–166, https://doi.org/10.1016/j.ccr.2012.06.005 (2012).
 8. Lilljebjorn, H. et al. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute 
lymphoblastic leukaemia. Nature communications 7, 11790, https://doi.org/10.1038/ncomms11790 (2016).
 9. Yasuda, T. et al. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet 48, 
569–574, https://doi.org/10.1038/ng.3535 (2016).
 10. Zhang, J. et al. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet 48, 1481–1489, https://doi.org/10.1038/
ng.3691 (2016).
 11. Rickert, R. C. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nature reviews. Immunology 13, 
578–591, https://doi.org/10.1038/nri3487 (2013).
 12. Eswaran, J. et al. The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia. Leukemia 29, 1623–1631, https://doi.
org/10.1038/leu.2015.113 (2015).
 13. Srinivasan, L. et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 139, 573–586, https://doi.org/10.1016/j.
cell.2009.08.041 (2009).
 14. Herzog, S., Reth, M. & Jumaa, H. Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nature 
reviews. Immunology 9, 195–205, https://doi.org/10.1038/nri2491 (2009).
 15. Lee, C. S., Rattu, M. A. & Kim, S. S. A review of a novel, Bruton’s tyrosine kinase inhibitor, ibrutinib. Journal of oncology pharmacy 
practice: official publication of the International Society of Oncology Pharmacy Practitioners 22, 92–104, https://doi.
org/10.1177/1078155214561281 (2016).
 16. Wang, Y., Zhang, L. L., Champlin, R. E. & Wang, M. L. Targeting Bruton’s tyrosine kinase with ibrutinib in B-cell malignancies. 
Clinical pharmacology and therapeutics 97, 455–468, https://doi.org/10.1002/cpt.85 (2015).
 17. Wiestner, A. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica 
100, 1495–1507, https://doi.org/10.3324/haematol.2014.119123 (2015).
 18. Kim, E. et al. Ibrutinib inhibits pre-BCR + B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood 129, 
1155–1165, https://doi.org/10.1182/blood-2016-06-722900 (2017).
 19. Muschen, M. Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia. Blood 125, 
3688–3693, https://doi.org/10.1182/blood-2015-01-567842 (2015).
 20. Kohrer, S. et al. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and 
can be targeted by SYK inhibition. Leukemia 30, 1246–1254, https://doi.org/10.1038/leu.2016.9 (2016).
 21. van der Veer, A. et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 
expression, in children with B-cell precursor ALL. Blood 122, 2622–2629, https://doi.org/10.1182/blood-2012-10-462358 (2013).
 22. Huang, H. et al. Defining the specificity space of the human SRC homology 2 domain. Mol Cell Proteomics 7, 768–784, https://doi.
org/10.1074/mcp.M700312-MCP200 (2008).
 23. Kaneko, T. et al. Loops govern SH2 domain specificity by controlling access to binding pockets. Sci Signal 3, ra34, https://doi.
org/10.1126/scisignal.2000796 (2010).
 24. Ohya, K. et al. Molecular cloning of a docking protein, BRDG1, that acts downstream of the Tec tyrosine kinase. Proceedings of the 
National Academy of Sciences of the United States of America 96, 11976–11981 (1999).
 25. Yokohari, K. et al. Isoform-dependent interaction of BRDG1 with Tec kinase. Biochemical and biophysical research communications 
289, 414–420, https://doi.org/10.1006/bbrc.2001.6008 (2001).
 26. Stoecker, K. et al. Induction of STAP-1 promotes neurotoxic activation of microglia. Biochemical and biophysical research 
communications 379, 121–126, https://doi.org/10.1016/j.bbrc.2008.12.021 (2009).
 27. Masuhara, M. et al. Molecular cloning of murine STAP-1, the stem-cell-specific adaptor protein containing PH and SH2 domains. 
Biochemical and biophysical research communications 268, 697–703, https://doi.org/10.1006/bbrc.2000.2223 (2000).
www.nature.com/scientificreports/
1 2SCiENTifiC REPORts |  (2018) 8:693  | DOI:10.1038/s41598-017-17704-4
 28. Harvey, R. C. et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene 
expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 116, 
4874–4884, https://doi.org/10.1182/blood-2009-08-239681 (2010).
 29. Clappier, E. et al. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia 
with a favorable outcome despite frequent IKZF1 deletions. Leukemia 28, 70–77, https://doi.org/10.1038/leu.2013.277 (2014).
 30. Zaliova, M. et al. ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute 
lymphoblastic leukemia. Leukemia 28, 182–185, https://doi.org/10.1038/leu.2013.282 (2014).
 31. Liu, Y. F. et al. Genomic Profiling of Adult and Pediatric B-cell Acute LymphoblasticLeukemia. EbioMedicine 8, 173–183, https://doi.
org/10.1016/j.ebiom.2016.04.038 (2016).
 32. Zhou, X. et al. Exploring genomic alteration in pediatric cancer using ProteinPaint. Nat Genet 48, 4–6, https://doi.org/10.1038/
ng.3466 (2016).
 33. Reddy, E. S. & Rao, V. N. erg, an ets-related gene, codes for sequence-specific transcriptional activators. Oncogene 6, 2285–2289 
(1991).
 34. Loughran, S. J. et al. The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic 
stem cells. Nat Immunol 9, 810-819, https://doi.org/10.1038/ni.1617 (2008).
 35. Sorensen, P. H. et al. A second Ewing’s sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription 
factor, ERG. Nat Genet 6, 146–151, https://doi.org/10.1038/ng0294-146 (1994).
 36. Kumar-Sinha, C., Tomlins, S. A. & Chinnaiyan, A. M. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8, 497–511, 
doi:nrc2402 [pii]10.1038/nrc2402 (2008).
 37. Marcucci, G. et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal 
karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 23, 9234–9242, https://doi.org/10.1200/JCO.2005.03.6137 (2005).
 38. van Geel, M. et al. Genomic analysis of human chromosome 10q and 4q telomeres suggests a common origin. Genomics 79, 
210–217, https://doi.org/10.1006/geno.2002.6690S0888754302966905 (2002).
 39. Kowaljow, V. et al. The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. Neuromuscular disorders: NMD 17, 
611–623, https://doi.org/10.1016/j.nmd.2007.04.002 (2007).
 40. Den Boer, M. L. et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute 
lymphoblastic leukemia. J Clin Oncol 21, 3262–3268, https://doi.org/10.1200/JCO.2003.11.031 (2003).
 41. Escherich, G., Zimmermann, M. & Janka-Schaub, G. & CoALL study group. Doxorubicin or daunorubicin given upfront in a 
therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison 
in trial CoALL 07-03. Pediatr Blood Cancer 60, 254–257, https://doi.org/10.1002/pbc.24273 (2013).
 42. Veerman, A. J. et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch 
Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004). Lancet Oncol 10, 957-966, doi:S1470-2045(09)70228-1 [pii] 
https://doi.org/10.1016/S1470-2045(09)70228-1 (2009).
 43. Escherich, G. et al. The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute 
lymphoblastic leukemia of childhood (CoALL 06-97). Haematologica 96, 854-862, https://doi.org/10.3324/haematol.2010.039735 
(2011).
 44. Kamps, W. A. et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and 
treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991–1996). Leukemia 16, 1099–1111, https://doi.
org/10.1038/sj.leu.2402489 (2002).
 45. Pieters, R. et al. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal 
Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. J Clin Oncol 34, 2591–2601, https://doi.
org/10.1200/JCO.2015.64.6364 (2016).
 46. Boer, J. M. et al. Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by 
high non-response and relapse rates. Haematologica 100, e261–264, https://doi.org/10.3324/haematol.2014.117424 (2015).
 47. van de Wiel, M. A. et al. CGHcall: calling aberrations for array CGH tumor profiles. Bioinformatics 23, 892–894, https://doi.
org/10.1093/bioinformatics/btm030 (2007).
 48. van Houte, B. P., Binsl, T. W., Hettling, H., Pirovano, W. & Heringa, J. CGHnormaliter: an iterative strategy to enhance normalization 
of array CGH data with imbalanced aberrations. BMC genomics 10, 401, https://doi.org/10.1186/1471-2164-10-401 (2009).
 49. Gray, R. J. cmprsk: Subdistribution Analysis of Competing Risks. R package version 2.2-6. http://CRAN.R-project.org/
package=cmprsk (2013).
 50. De Wreede, L. C., Fiocco, M. & Putter, H. mstate: An R Package for the Analysis of Competing Risks and Multi-State Models. J Stat 
Softw 38, 1–30 (2011).
 51. Therneau, T. A Package for Survival Analysis in S. R package version 2.36-12 (2012).
 52. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. Journal of molecular biology 215, 
403–410, https://doi.org/10.1016/S0022-2836(05)80360-2 (1990).
Acknowledgements
This work was supported by the VICI program grant 016.126.612 from Netherlands Organisation for Scientific 
Research (NWO), the Dutch Cancer Society grants AMC 2008-4265 and EMCR 2014-6998, the Kika Foundation 
(grant 132 and 161) and the Pediatric Oncology Foundation Rotterdam. This work was supported in part by US 
NIH Center for Precision Medicine of Leukemia grant P50 GM115279, and we thank William Evans, Jun Yang, 
and Kristine Crews of St. Jude Children’s Research Hospital for the RNAseq analyses.
Author Contributions
E.M.P.S. designed and performed experiments, and analyzed and interpreted data. M.B., Q.H., and F.S. performed 
experiments. A.Q.H. analyzed SNP. arrays and RNAseq data. J.M.B. designed experiments and interpreted data. 
R.P., H.A.d.G.K., V.d.H., and G.E. provided clinical characteristics, clinical outcome data, and interpreted data. 
R.P. and M.L.d.B. conceptualized the study, and interpreted data. E.M.P.S. and M.L.d.B. drafted the manuscript. 
The manuscript was revised and approved by all authors.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-17704-4.
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
www.nature.com/scientificreports/
13SCiENTifiC REPORts |  (2018) 8:693  | DOI:10.1038/s41598-017-17704-4
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
